Literature DB >> 7625721

Pharmacological properties of a new selective antiprogestagen: Org 33628.

H J Kloosterboer1, G H Deckers, M E de Gooyer, R Dijkema, E O Orlemans, W G Schoonen.   

Abstract

UNLABELLED: For antiprogestagens both selectivity (ratio of antiprogestational to antiglucocorticoid activity) and potency are important conditions for their applications in fertility regulation and correction of hormone-dependent irregularities. Org 33628 appears to fulfill both conditions most convincingly. The activities of this new antiprogestagen in various assays are compared with those of RU 38486 and a few other antiprogestagens. The binding of Org 33628 to the progesterone receptor is twice as high as that of RU 38486 whereas the binding to the glucocorticoid receptor is 25 times lower than that of RU 38486. The activity of Org 33628 in the pregnancy interruption test in rats is 16 times higher than that of RU 38486. The antiglucocorticoid activity of Org 33628 in rats is about eight times lower than that of RU 38486. In the ovulation inhibition test in rats Org 33628 is approximately 80 times more potent than RU 38486. For menses induction in the stumptail monkey activity observed for Org 33628 is only twice as high. IN
CONCLUSION: Org 33628 is a very potent and selective antiprogestagen with a remarkably high ovulation-inhibitory activity. The magnitude of the potency difference with RU 38486 is species and/or target organ dependent.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7625721     DOI: 10.1111/j.1749-6632.1995.tb31379.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  4 in total

1.  Comparison between steroid binding to membrane progesterone receptor alpha (mPRalpha) and to nuclear progesterone receptor: correlation with physicochemical properties assessed by comparative molecular field analysis and identification of mPRalpha-specific agonists.

Authors:  Jan Kelder; Rita Azevedo; Yefei Pang; Jacob de Vlieg; Jing Dong; Peter Thomas
Journal:  Steroids       Date:  2010-01-22       Impact factor: 2.668

2.  The X-ray structure of RU486 bound to the progesterone receptor in a destabilized agonistic conformation.

Authors:  Hans C A Raaijmakers; Judith E Versteegh; Joost C M Uitdehaag
Journal:  J Biol Chem       Date:  2009-04-16       Impact factor: 5.157

3.  Discovery of Vilaprisan (BAY 1002670): A Highly Potent and Selective Progesterone Receptor Modulator Optimized for Gynecologic Therapies.

Authors:  Carsten Möller; Wilhelm Bone; Arwed Cleve; Ulrich Klar; Andrea Rotgeri; Antje Rottmann; Marcus-Hillert Schultze-Mosgau; Andrea Wagenfeld; Wolfgang Schwede
Journal:  ChemMedChem       Date:  2018-11-06       Impact factor: 3.466

4.  The selective glucocorticoid receptor antagonist CORT125281 has tissue-specific activity.

Authors:  Lisa L Koorneef; Jan Kroon; Eva M G Viho; Lucas F Wahl; Kim M L Heckmans; Marloes M A R van Dorst; Menno Hoekstra; René Houtman; Hazel Hunt; Onno C Meijer
Journal:  J Endocrinol       Date:  2020-07       Impact factor: 4.286

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.